

Curriculum Vitae

Stefan Engelhardt Prof. Dr. med., Dr. rer. nat.
d.o.b. June 04th, 1969, in Munich, Germany

University Education

2001 PhD thesis, University of Wuerzburg
1995 MD thesis, Max-Planck-Institute of Biochemistry
1989-1996 Studies in Medicine, Universities of Regensburg, Munich (Germany) and Harvard (USA)

Scientific Career

since 2026 Co-Coordinator Excellence-Cluster NUCLEATE
since 2023 Co-Coordinator of the Future-Cluster CNATM
since 2019 Coordinator of the Collaborative Research Centre TRR/SFB 267 “Non-coding RNA in the cardiovascular system”
2013-2019 Vice Dean for Research, TUM School of Medicine
2011-2020 Coordinator of the Munich site within the German Center for Cardiovascular Research (DZHK)
2011-2013 Member of the Executive Board of the German Cardiac Society (DGK)
2010-2013 Vice-Chair and Chair (2011) of the Commission for Experimental Cardiology of the German Cardiac Society (DGK)
since 2008 Full Professor and Chair (W3), Institute of Pharmacology and Toxicology, Technical University Munich (TUM)
2005-2008 Professor of Clinical Pharmacology at the University of Wuerzburg (W2)
2004-2008 Group Leader, Rudolf Virchow Center, DFG-Research Center for Experimental Biomedicine, University of Wuerzburg
2003-2004 Appointment as Fellow in Cardiovascular Research, Massachusetts General Hospital, Harvard Medical School, Boston
1999-2003 Postdoctoral position at the Institute for Pharmacology and Toxicology, Bayerische Julius-Maximilians-Universität Wuerzburg

Awards and Honors

2025 Heinz-Maier-Leibnitz medal
2025 Member of Leopoldina
2022 Fellow of the ISHR
2021 Founder, rnatix GmbH
2013 Badge of Honour of German Cardiac Society
2009 Outstanding Achievement Award of the European Society of Cardiology
2006 Outstanding Early Career Award (Finalist) of the American Heart Association
2006 Arthur-Weber-Award of the German Cardiac Society
2005 European Young Investigator Award (European Society of Cardiology)
2005 Oskar Lapp Award of the German Cardiac Society
2004 Biology-Award of the Akademie der Wissenschaften zu Göttingen
2004 Hengstberger Prize of the German Cardiac Society
2002 Outstanding Research Award of the American Heart Association
2000 Fritz-Külz-Award of the German Society of Pharmacology
1999 Award of the Medical Faculty for the most outstanding MD thesis

Citation Record

Total citations: 21,044; h-index:66; h-index since 2021: 42 (Google Scholar July 20th, 2022)

Top-10 selected Publications

Ziegler KA, Zeitler M, Meunier S, Sinicina I, Hasenbein T, Andergassen D, Bomhard A, Van Der Kwast R.V.C.T, **Engelhardt S**. Ganglionic Inflammation in a Patient With Takotsubo Syndrome. **Circulation**. 2025; 151(12). doi: [10.1161/CIRCULATIONAHA.124.070862](https://doi.org/10.1161/CIRCULATIONAHA.124.070862).

Ziegler KA, Ahles A, Dueck A, Esfandyari D, Pichler P, Weber K, Kotschi S, Bartelt A, Sinicina I, Graw M, Leonhardt H, Weckbach LT, Massberg S, Schifferer M, Simons M, Hoeher L, Luo J, Ertürk A, Schiattarella GG, Sassi Y, Misgeld T, **Engelhardt S**. Immune-mediated denervation of the pineal gland underlies sleep disturbance in cardiac disease. **Science** 2023; 381(6655):285-290. doi: [10.1126/science.abn6366](https://doi.org/10.1126/science.abn6366).

Beck C, Ramanujam D, Vaccarello P, Widenmeyer F, Feuerherd M, Cheng CC, Bomhard A, Abikeeva T, Schädler J, Sperhake JP, Graw M, Safi S, Hoffmann H, Staab-Weijnitz CA, Rad R, Protzer U, Frischmuth T, **Engelhardt S**. Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage. **Nat Commun** 2023;14(1):4564. doi: [10.1038/s41467-023-40185-1](https://doi.org/10.1038/s41467-023-40185-1).

Esfandyari D, Idrissou B, Hennis K, Avramopoulos P, Dueck A, El-Battrawy I, Grüter L, Meier M, Näger A, Ramanujam D, Dorn T, Meitinger T, Hagl C, Milting H, Borggreffe M, Fenske S, Bie MI, Dendorfer A, Sassi Y, Moretti A, **Engelhardt S**. MicroRNA-365 regulates human cardiac action potential duration. **Nat Commun** 11:13:220, 2022, doi: [10.1038/s41467-021-27856-7](https://doi.org/10.1038/s41467-021-27856-7).

Ramanujam D, Schön AP, Beck C, Vaccarello P, Felician G, Dueck A, Esfandyari D, Meister G, Meitinger T, Schulz C, **Engelhardt S**. MiR-21-dependent macrophage-to-fibroblast signaling determines the cardiac response to pressure overload. **Circulation** 143 1513–1525, 2021, doi: [10.1161/CIRCULATIONAHA.120.050682](https://doi.org/10.1161/CIRCULATIONAHA.120.050682).

Sassi Y, Avramopoulos P, Ramanujam D, Grüter L, Werfel S, Giosele S, Brunner A-D, Esfandyari D, Papadopoulou AS, De Strooper B, Hubner N, Kumarswamy R, Thum T, Yin X, Mayr M, Laggerbauer B, **Engelhardt S**. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. **Nat Commun** 8:1614, 2017, doi: [10.1038/s41467-017-01737-4](https://doi.org/10.1038/s41467-017-01737-4).

Werfel S, Leierseder S, Ruprecht B, Kuster B, **Engelhardt S**. Preferential microRNA targeting revealed by in vivo competitive binding and differential argonaute immunoprecipitation. **Nucleic Acids Res** 45:10218–10228, 2017, doi: [10.1093/nar/gkx640](https://doi.org/10.1093/nar/gkx640).

Sassi Y, Ahles A, Truong DJ, Baqi Y, Lee SY, Husse B, Hulot JS, Foinquinos A, Thum T, Müller CE, Dendorfer A, Laggerbauer B, **Engelhardt S**. Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. **J Clin Invest** 124:5385-5397, 2014, doi: [10.1172/JCI74349](https://doi.org/10.1172/JCI74349).

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliensky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, **Engelhardt S**. MicroRNA- 21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. **Nature** 456:980-984, 2008, doi: [10.1038/nature07511](https://doi.org/10.1038/nature07511).

Buitrago M, Lorenz K, Maass AH, Oberdorf-Maass S, Keller U, Schmitteckert EM, Ivashchenko Y, Lohse MJ, **Engelhardt S**. The transcriptional repressor NAB1 is a specific regulator of pathological cardiac hypertrophy. **Nat Med** 11: 837-844, 2005, doi: [10.1038/nm1272](https://doi.org/10.1038/nm1272).